心血管代谢疾病分期预测减重治疗预防2型糖尿病的有效性:芬特明/托吡酯缓释剂III期临床试验汇总结果
汇总CONQUER、EQUIP和SEQUEL三项随机对照试验共3040例超重/肥胖成人数据,评估基线加权心血管代谢疾病分期(CMDS)评分与药物辅助减重预防糖尿病效果的关系。结果显示CMDS高危组1年糖尿病发病率绝对下降幅度最大(10.43%至6.29%),预防1例糖尿病需治疗人数(NNT)在高危组为24、中危组43、低危组120。
要点
- 基线CMDS评分越高,药物减重预防糖尿病的绝对获益越大。
- 56周内预防1例糖尿病NNT:CMDS≥60组24、30-59组43、0-29组120。
- CMDS可量化超重/肥胖个体糖尿病风险并预测减重治疗预防糖尿病的效果。
核心结论
- 在高危CMDS评分患者中,预防1例2型糖尿病所需的NNT明显更低。
- CMDS可用于量化超重/肥胖个体的糖尿病风险,并预测减重治疗预防糖尿病的有效性。
研究设计与样本
- 汇总三项随机对照试验(CONQUER、EQUIP、SEQUEL)共3040例超重和肥胖参与者的数据。
- 三项均为双盲III期试验,评估芬特明/托吡酯缓释剂(ER)减重的疗效与安全性。
- 超重/肥胖成人接受生活方式干预,随机分配至安慰剂组或每日一次口服芬特明/托吡酯缓释剂组。
- 加权CMDS评分基于基线定量临床数据计算,包括腰围、血糖、血压和血脂。
- 新发糖尿病根据空腹血糖、2小时口服葡萄糖耐量试验血糖和/或HbA1c的系列测量定义。
主要发现
- 1年糖尿病发病率绝对下降值在基线CMDS高危组最大(10.43%至6.29%),中危组居中(4.67%至2.37%),低危组较小(1.51%至0.67%)。
- 56周内预防1例新发糖尿病需治疗人数在基线CMDS评分≥60组为24、30-59组为43、0-29组为120。
关键数值与推荐
- 基线CMDS评分≥60组:56周NNT为24。
- 基线CMDS评分30-59组:56周NNT为43。
- 基线CMDS评分0-29组:56周NNT为120。
- 高危CMDS组1年糖尿病发病率由10.43%降至6.29%(药物 vs 安慰剂)。
- 中危CMDS组1年糖尿病发病率由4.67%降至2.37%(药物 vs 安慰剂)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the ability of medication-assisted weight loss to prevent diabetes as a function of the baseline weighted Cardiometabolic Disease Staging (CMDS) score. RESEARCH DESIGN AND METHODS: We pooled data from 3,040 overweight and obese participants in three randomized controlled trials-CONQUER, EQUIP, and SEQUEL-assessing efficacy and safety of phentermine/topiramate extended release (ER) for weight loss. In these double-blind phase III trials, overweight/obese adult patients were treated with a lifestyle intervention and randomly assigned to placebo versus once-daily oral phentermine/topiramate ER. The weighted CMDS score was calculated using baseline quantitative clinical data including waist circumference, blood glucose, blood pressure, and blood lipids. Incident diabetes was defined based on serial measures of fasting glucose, 2-h oral glucose tolerance test glucose, and/or HbA1c. RESULTS: The absolute decrease in 1-year diabetes incidence rates in subjects treated with medication versus placebo was greatest in those with high-risk CMDS scores at baseline (10.43-6.29%), intermediate in those with moderate CMDS risk (4.67-2.37%), and small in the low-risk category (1.51-0.67%). The number of participants needed to treat to prevent one new case of diabetes over a 56-week period was 24, 43, and 120 in those with baseline CMDS scores of ≥60, 30-59, and 0-29, respectively. CONCLUSIONS: Numbers needed to treat to prevent one case of type 2 diabetes are markedly lower in patients with high-risk scores. CMDS can be used to quantify risk of diabetes in overweight/obese individuals and predict the effectiveness of weight-loss therapy to prevent diabetes.
引用
- Guo F, Garvey WT. Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release. Diabetes Care. 2017. PMID: 28455281. doi:10.2337/dc17-0088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。